化合物简介
Cariprazine (trade name Vraylar, previously known as RGH-188) is an antipsychotic drug developed by Gedeon Richter. It acts as a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. Positive Phase III study results were published for schizophrenia and mania in early 2012, and for bipolar disorder I depression from a Phase II trial in 2015. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder ; Rights are currently owned by Gedeon Richter and Actavis. The drug received FDA approval on September 17, 2015.
基本信息
中文名称
卡利拉嗪
英文名称
3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
中文别名
英文别名
Cariprazine、trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea、Cariprazine (USAN/INN)、3-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea、trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine、RGH 188、UNII-F6RJL8B278、trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine
CAS号
839712-12-8
分子式
C21H32Cl2N4O
分子量
427.411
精确质量
426.195
PSA
42.31
LOGP
4.5428
编号系统
UNII
F6RJL8B278
合成路线
共找到1条合成路线 >上游原料
共找到7个上游原料 >